A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- The Cleveland Clinic
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Change in Serum Alkaline Phosphatase Levels.
Study Overview
Brief Summary
Primary biliary cirrhosis (PBC) is cholestatic liver disease characterized by progressive destruction of small bile ducts within the liver that can lead to end stage liver disease and all its complications.
Although ursodeoxycholic acid (UDCA) is associated with increased survival in many patients with PBC, there is absence of an adequate response to UDCA in a significant proportion of PBC patients.
Tumor necrosis factor alpha (TNF-alpha) is a cytokine that plays an important role in the pathogenesis of PBC. Other fibrosis biomarkers such as tissue metallo proteinase 1 (TIMP-1) are associated with progression of liver fibrosis in PBC. Pentoxifylline (PTX) is a methylxanthine derivative that inhibits pro-inflammatory cytokines and also has shown anti-fibrotic effects in serum of patients with PBC. Furthermore, PTX has well known clinical and safety profiles. The main hypothesis of this study is that therapy with pentoxifylline (PTX) will result in improvement of liver disease in PBC patients who are incomplete responders to UDCA.
The focus of this proposal is on the effectiveness of PTX in improving laboratory parameters of liver disease and levels of cytokines involved in the pathogenesis of the disease in patients with PBC.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 76 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and female patients ages 18 to 76 years.
- •Established diagnosis of PBC based on at least three of the following criteria:
- •Detectable anti-mitochondrial antibodies (AMA)
- •Cholestatic biochemical pattern
- •Liver biopsy compatible with PBC
- •Appropriate exclusion of other liver diseases.
- •Therapy with UDCA at adequate dose (13-15mg/kg/d) for at least six months and evidence of suboptimal response defined by alkaline phosphatase levels that did not normalize and remain elevated by at least 1.5 times the upper limit of normal.
- •No history or present hepatic decompensation (e.g. variceal hemorrhage, encephalopathy, or poorly controlled ascites).
Exclusion Criteria
- •Findings highly suggestive of liver disease of other etiology.
- •A score >=10 points on the Revised Scoring System for autoimmune hepatitis (AIH), supporting a diagnosis of PBC/AIH overlap.
- •Patients on steroids (systemic), immunosuppressants, or immunomodulatory agents within the previous 6 months.
- •Patients with clinical or laboratory evidence suggestive of decompensated cirrhosis.
- •Hypersensitivity to PTX or the methylxanthines (caffeine, theophylline, theobromine).
- •History of cerebral or retinal hemorrhage.
- •Other medical comorbidities (such as cardiac, renal, cancer) that would interfere with completion of the study.
- •Patients taking Theophylline or Coumadin because of potential drug-drug interactions with PTX. In addition, patients taking low molecular weight heparin preparations.
- •Pregnant or nursing women.
Arms & Interventions
Pentoxifylline 400 mg TID
This study is an open label pilot with only one arm.
Intervention: Pentoxifylline (Drug)
Outcomes
Primary Outcomes
Change in Serum Alkaline Phosphatase Levels.
Time Frame: 6 months
Serum alkaline phosphatase levels at entry and at 6 months of therapy with PTX will be measured and compared.
Secondary Outcomes
- Change in Serum Concentration of Tissue Inhibitor Metalloproteinase 1 (TIMP-1) After PTX Therapy.(6 months)
- Safety of Therapy in the Pilot Study of PTX Therapy in Patients With PBC Will be Assessed(6 months)
Investigators
Claudia Zein, MD
Staff Physician, Digestive Disease Institute
The Cleveland Clinic